NCT07774871

Brief Summary

To evaluate whether routine ureterolysis during Total Laparoscopic Hysterectomy for benign gynecologic conditions affects operative efficiency and perioperative safety compared with a selective ureterolysis approach.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
7mo left

Started Aug 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Aug 2026Apr 2027

First Submitted

Initial submission to the registry

August 16, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 19, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

August 21, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 28, 2027

Last Updated

August 19, 2026

Status Verified

August 1, 2026

Enrollment Period

6 months

First QC Date

August 16, 2026

Last Update Submit

August 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total operative duration

    Total operative duration in minutes measured from skin incision to skin closure

    day 0

Secondary Outcomes (1)

  • time needed for ureterolysis

    day 0

Study Arms (2)

Routine Ureterolysis

EXPERIMENTAL

Intervention Group: Routine Ureterolysis

Procedure: Routine Ureterolysis

Selective Ureterolysis

ACTIVE COMPARATOR

Control group: selective Ureterolysis

Procedure: Selective Ureterolysis

Interventions

for all cases of the group: After entering the pelvis and before uterine vessel ligation, routine bilateral ureterolysis will be performed. The retroperitoneal space will be opened by incising the peritoneum overlying the ureter, followed by careful blunt and sharp dissection to identify each ureter and trace its course from the pelvic brim toward the uterine artery and ureteric tunnel. Surrounding tissue will be dissected only to the extent necessary to obtain clear visualization and safe lateralization of the ureter before completing the hysterectomy. Excessive skeletonization, thermal spread, and disruption of the ureteral blood supply will be avoided. The procedure will be performed using a standardized technique and documented in the operative record.

Routine Ureterolysis

for selected cases of the group: After entering the pelvis and before uterine vessel ligation, routine bilateral ureterolysis will be performed. The retroperitoneal space will be opened by incising the peritoneum overlying the ureter, followed by careful blunt and sharp dissection to identify each ureter and trace its course from the pelvic brim toward the uterine artery and ureteric tunnel. Surrounding tissue will be dissected only to the extent necessary to obtain clear visualization and safe lateralization of the ureter before completing the hysterectomy. Excessive skeletonization, thermal spread, and disruption of the ureteral blood supply will be avoided. The procedure will be performed using a standardized technique and documented in the operative record.

Selective Ureterolysis

Eligibility Criteria

Age35 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women aged 35-70 years
  • Scheduled for TLH for benign indications:
  • Symptomatic fibroids, Abnormal uterine bleeding, Adenomyosis, Endometrial hyperplasia, Pelvic organ prolapse requiring hysterectomy, Chronic pelvic pain, Uterine size ≤16 weeks

You may not qualify if:

  • Previous pelvic radiation
  • Known ureteric abnormalities or pathology
  • Severe cardiopulmonary disease precluding laparoscopy
  • Inability to provide informed consent
  • Known retroperitoneal pathology
  • Emergency surgery
  • Uterine size \> 16 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kasr Alaini gynecology and obstetrics hospital

Cairo, Cairo Governorate, 11472, Egypt

Location

Central Study Contacts

Mostfa MA Saad, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Participants and postoperative outcome assessors will be blinded to treatment allocation. Because of the nature of the surgical interventions, the operating surgeons cannot be blinded. Data analysts will remain blinded to group allocation, with the intervention groups coded and their identities concealed until the primary analysis has been completed.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized controlled parallel study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

August 16, 2026

First Posted

August 19, 2026

Study Start

August 21, 2026

Primary Completion (Estimated)

February 28, 2027

Study Completion (Estimated)

April 28, 2027

Last Updated

August 19, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations